Metformin vs Tesamorelin
FDA Approved vs FDA Approved
compatible Researched · 90% May mitigate glucose intolerance associated with tesamorelin.
Molecular Data
Metformin Tesamorelin
Weight 129.16 Da 5,135.9 Da
Half-life ~5 hours 26-38 minutes
Chain — 44 amino acids
Type Biguanide (C4H11N5) GHRH analog
Key Benefits
Metformin
01 Improved insulin sensitivity and glucose regulation
02 Activation of AMPK, the master metabolic energy sensor
03 Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)
04 Reduced hepatic glucose output (gluconeogenesis suppression)
05 Modest weight loss or weight neutrality compared to other diabetes medications
06 Anti-inflammatory effects through NF-kB pathway suppression
07 Potential anti-cancer properties via mTOR inhibition and AMPK activation
08 Improved lipid profile with modest reductions in LDL cholesterol and triglycerides
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
Metformin
500-2000 mg/day / 1-2x daily with meals
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
Metformin
Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users
Metallic taste in mouth
Decreased appetite
Flatulence and abdominal distension
Loose stools, particularly when initiating therapy or increasing dose
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Severe renal impairment (eGFR below 30 mL/min/1.73m2)
Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Known hypersensitivity to metformin
Acute conditions with potential for tissue hypoxia (decompensated heart failure, respiratory failure, recent MI, sepsis)
Severe hepatic impairment
Excessive alcohol intake (increases risk of lactic acidosis)
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
Metformin Tesamorelin
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest 2023 June 2025
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.